Search Result

Results for "

dyskinesias

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (8) Adenosine Receptor (1) Adrenergic Receptor (6) Amyloid-β (1) Apoptosis (1) Biochemical Assay Reagents (2) Dopamine Receptor (20) Endogenous Metabolite (3) ERK (1) FAAH (1) GABA Receptor (1) GSK-3 (2) Histone Methyltransferase (5) Imidazoline Receptor (1) Isotope-Labeled Compounds (1) mGluR (5) Monoamine Oxidase (3) Monoamine Transporter (1) Opioid Receptor (2) Phospholipase (2) Reference Standards (1) Reverse Transcriptase (3) Serotonin Transporter (1) Tau Protein (2) Transmembrane Glycoprotein (1) β-catenin (1)
By Research Areas:	Cancer (9) Endocrinology (6) Metabolic Disease (2) Neurological Disease (43)

By Targets:

5-HT Receptor (8)

Adenosine Receptor (1)

Adrenergic Receptor (6)

Amyloid-β (1)

Apoptosis (1)

Biochemical Assay Reagents (2)

Dopamine Receptor (20)

Endogenous Metabolite (3)

ERK (1)

FAAH (1)

GABA Receptor (1)

GSK-3 (2)

Histone Methyltransferase (5)

Imidazoline Receptor (1)

Isotope-Labeled Compounds (1)

mGluR (5)

Monoamine Oxidase (3)

Monoamine Transporter (1)

Opioid Receptor (2)

Phospholipase (2)

Reference Standards (1)

Reverse Transcriptase (3)

Serotonin Transporter (1)

Tau Protein (2)

Transmembrane Glycoprotein (1)

β-catenin (1)

By Research Areas:

Cancer (9)

Endocrinology (6)

Metabolic Disease (2)

Neurological Disease (43)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12723

Apomorphine Maximum Cited Publications 6 Publications Verification (-)-Apomorphine	Dopamine Receptor 5-HT Receptor	Neurological Disease
Apomorphine is an orally active agonist of Dopamine receptor. Apomorphine can be used in study Parkinson, biphasic dyskinesias, urinary dysfunction,,dystonia, dyspnoea, anismus and belching .

HY-108242

Apomorphine hydrochloride Maximum Cited Publications 6 Publications Verification (-)-Apomorphine hydrochloride	Dopamine Receptor 5-HT Receptor	Neurological Disease
Apomorphine ((-)-Apomorphine) hydrochloride is an orally active agonist of Dopamine receptor. Apomorphine hydrochloride can be used in study Parkinson, biphasic dyskinesias, urinary dysfunction, dystonia, dyspnoea, anismus and belching .

HY-14859

Dipraglurant ADX48621	mGluR	Neurological Disease
Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant mGluR5 negative allosteric modulator (NAM), with an IC₅₀ of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo . Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

HY-15257

Mavoglurant 3 Publications Verification AFQ056	mGluR	Neurological Disease
Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC₅₀ of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-153472

VMAT2-IN-2 tosylate	Monoamine Transporter	Neurological Disease
VMAT2-IN-2 tosylate is a potent VMAT2 inhibitor. VMAT2-IN-2 tosylate can be used in research of tardive dyskinesia .

HY-118238

Remeglurant MRZ-8456	mGluR	Neurological Disease
Remeglurant (MRZ-8456) acts as a selective, orally active and allosteric antagonist of the mGlu5 receptor, with an IC₅₀ of 13 nM. Remeglurant (MRZ-8456) can be used in the research for dyskinesia in Parkinson’s disease (PD) .

HY-105034A

Tiospirone hydrochloride BMY 13859-1; MJ 13859-1	5-HT Receptor	Neurological Disease
Tiospirone (MJ 13859-1) hydrochloride is an orally active antipsychotic agent that reduces or eliminates tardive dyskinesia (TD) in Cebus apella monkeys with persistent TD .

HY-167899

PXT-012253	mGluR	Neurological Disease
PXT-012253 is a positron emission tomography (PET) ligand for mGluR4, as it binds to an allosteric site on mGluR4. PXT-012253 can be utilized in researches related to Parkinson's disease and levodopa-induced dyskinesia .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-B1744

Pyridoxal phosphate 1 Publications Verification Pyridoxal 5′-phosphate; Pyridoxyl phosphate	Reverse Transcriptase Endogenous Metabolite ERK Amyloid-β	Neurological Disease Metabolic Disease Cancer
Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia.

HY-16771B

Valbenazine dihydrochloride NBI-98854 dihydrochloride	Dopamine Receptor	Neurological Disease
Valbenazine (NBI-98854) dihydrochloride is a VMAT2 inhibitor, used to treat tardive dyskinesia. Valbenazine dihydrochloride demonstrates potential benefit in alleviating symptoms associated with movement disorders resulting from chronic dopamine receptor blocking medications. Valbenazine dihydrochloride has been supported by evidence from preclinical models examining its role in the genetic factors linked to tardive dyskinesia.

HY-N11021

Feruloyl tyramine	Others	Others
Feruloyl tyramine, an amide compound, can be isolated from ethanol extract of hemp seed. Feruloyl tyramine injected into the lateral ventricle caused hypothermia and dyskinesia in mice .

HY-B1744R

Pyridoxal phosphate (Standard)	Reverse Transcriptase Endogenous Metabolite	Neurological Disease
Pyridoxal phosphate (Standard) is the analytical standard of Pyridoxal phosphate. This product is intended for research and analytical applications. Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia.

HY-B1744S

Pyridoxal phosphate-d5	Isotope-Labeled Compounds Reverse Transcriptase Endogenous Metabolite	Neurological Disease
Pyridoxal phosphate-d₅ is the deuterium labeled Pyridoxal phosphate. Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia .

HY-Y1089

4-Dimethylaminopyridine	Biochemical Assay Reagents Transmembrane Glycoprotein	Others Neurological Disease
4-Dimethylaminopyridine is an acyl transfer catalyst. 4-Dimethylaminopyridine is used for labeling and analysis of glycoproteins on the surface of living cells. 4-Dimethylaminopyridine reduces dyskinesia attacks .

HY-109139A

Taminadenant mesylate NIR178 mesylate; PBF509 mesylate	Adenosine Receptor	Cancer
Taminadenant mesylate (NIR178 mesylate) is a potent adenosine A2A receptor antagonist with potential anti-tumor activity. Taminadenant mesylate can selectively bind and inhibit A2AR on T lymphocytes, thereby releasing adenosine/A2AR-mediated inhibition of T lymphocytes and activating T cell-mediated immune responses against tumor cells. Taminadenant mesylate works by reducing the proliferation of susceptible tumor cells. Taminadenant mesylate also showed effectiveness in reversing dyskinesias in Parkinson's disease models and was able to inhibit dyskinesias caused by L-DOPA .

HY-121203A

Citalopram oxalate	Serotonin Transporter	Neurological Disease
Citalopram oxalate is a serotonin uptake inhibitor that serves as an antidepressant, effectively reducing ethanol uptake in alcoholics and offering a preferable option for depressed patients experiencing tardive dyskinesia compared to tricyclic antidepressants, which may worsen this condition.

HY-Y1089R

4-Dimethylaminopyridine (Standard)	Biochemical Assay Reagents	Others
4-Dimethylaminopyridine (Standard) is the analytical standard of 4-Dimethylaminopyridine. This product is intended for research and analytical applications. 4-Dimethylaminopyridine is an acyl transfer catalyst. 4-Dimethylaminopyridine is used for labeling and analysis of glycoproteins on the surface of living cells. 4-Dimethylaminopyridine reduces dyskinesia attacks .

HY-19199

E-3620	5-HT Receptor	Neurological Disease Metabolic Disease
E-3620 is a potent 5-HT₃ receptor antagonist. E-3620 can be used for the research of dyskinesi and gastrointestinal motility .

HY-14561A

Idazoxan hydrochloride RX 781094 hydrochloride	Adrenergic Receptor Imidazoline Receptor	Neurological Disease Endocrinology
Idazoxan hydrochloride (RX 781094 hydrochloride) is an α₂-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like agents (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism .

HY-118956

Adrogolide hydrochloride ABT-431 hydrochloride; DAS-431 hydrochloride	Dopamine Receptor	Neurological Disease
Adrogolide hydrochloride (ABT-431 hydrochloride) is a chemically stable prodrug that can convert to the dopamine D1 receptor agonist A-86929. Adrogolide hydrochloride ameliorates the MPTP (HY-15608)-induced Parkinson's Disease in marmoset model, reduces the dyskinesias tendency. Adrogolide hydrochloride reverses Risperidone (HY-11018)-induced cognitive deficits in monkey .

HY-100820B

Sarizotan dihydrochloride EMD 128130 dihydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan dihydrochloride (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-100820A

Sarizotan hydrochloride EMD 128130 hydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan hydrochloride is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan hydrochloride (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-100820R

Sarizotan (Standard) EMD 128130 (Standard)	Reference Standards 5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan (Standard) is the analytical standard of Sarizotan. This product is intended for research and analytical applications. Sarizotan (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-100820

Sarizotan 1 Publications Verification EMD 128130	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-W116433

SK609	Dopamine Receptor	Neurological Disease
SK609 is a selective dopamine D3 receptor agonist with activity that improves dopamine and norepinephrine levels in the cerebral cortex. SK609 has been successfully used to suppress dyskinesias in Parkinson's disease models and alleviated muscle twitches induced by L-dopa. SK609 improved performance in sustained attention tasks by significantly reducing misses and false alarms. SK609 may provide an inhibitory option for suppressing movement and cognitive impairment in patients with Parkinson's disease .

HY-119093R

Halopemide (Standard)	Phospholipase Dopamine Receptor	Neurological Disease Cancer
Halopemide (Standard) is the analytical standard of Halopemide. This product is intended for research and analytical applications. Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .

HY-131678

Palmitoyl serotonin PA-5HT	FAAH	Neurological Disease
Palmitoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin, antagonist of FAAH. Palmitoyl serotonin inhibits L-3,4-dihydroxyphenylalanine (HY-N0304) induced abnormal involuntary movements. Palmitoyl serotonin has the potential for the research of parkinson's disease (PD) .

HY-176420

VU6031545	mGluR	Neurological Disease
VU6031545 is a potent mGlu 5 negative allosteric modulator with an IC₅₀ of 15 nM. VU6031545 has excellent brain penetrant and oral bioavailability in rats .

HY-119093

Halopemide	Phospholipase Dopamine Receptor	Neurological Disease Cancer
Halopemide is a potent phospholipase D (PLD) inhibitor, with IC₅₀s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .

HY-118931

EF-1502	GABA Receptor	Neurological Disease
EF-1502 is a potent and selective GABA transporter inhibitor with GAT1 and BGT1 inhibitory activity. EF-1502 produces a synergistic anti-epileptic effect when used in combination with Tiagabine (HY-B0696), a compound used to suppress epileptic seizures. The dosing combination of EF-1502 exhibited reduced anti-epileptic efficacy and dyskinesia when used with THIP (HY-10232). The mechanism of EF-1502 differs significantly from Tiagabine, suggesting a unique role in the inhibitory strategy .

HY-120206A

Brasofensine maleate BMS-204756 maleate	Monoamine Oxidase	Neurological Disease
Brasofensine maleate(BMS-204756) sulfate is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .

HY-120206

Brasofensine BMS-204756	Monoamine Oxidase	Neurological Disease
Brasofensine (BMS-204756) is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .

HY-120206B

Brasofensine sulfate BMS-204756 sulfate	Monoamine Oxidase	Neurological Disease
Brasofensine (BMS-204756) sulfate is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .

HY-168857

GSK-3β inhibitor 24	GSK-3 Tau Protein β-catenin	Neurological Disease
GSK-3β inhibitor 24 (Compound 41) is a potent GSK-3β inhibitor with an IC₅₀ of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects .

HY-12707

Piribedil 1 Publications Verification	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707A

Piribedil dihydrochloride	Adrenergic Receptor Dopamine Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a α2-adrenoceptors antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707B

Piribedil maleate	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil maleate is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil maleate is also a α2-adrenoceptors antagonist. Piribedil maleate can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil maleate has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707R

Piribedil (Standard)	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707C

Piribedil hydrochloride	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil hydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil hydrochloride is also a α2-adrenoceptors antagonist. Piribedil hydrochloride can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil hydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-149542

GSK-3β inhibitor 15	Tau Protein Apoptosis GSK-3	Neurological Disease
GSK-3β inhibitor 15 (Compound 54) is a GSK-3β inhibitor (IC₅₀: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ_1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ_1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .

HY-B1904R

Fluphenazine decanoate (Standard)	Dopamine Receptor	Neurological Disease
Fluphenazine decanoate (Standard) is the analytical standard of Fluphenazine decanoate. This product is intended for research and analytical applications. Fluphenazine decanoate is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .

HY-B1904

Fluphenazine decanoate	Dopamine Receptor	Neurological Disease
Fluphenazine decanoate is a dopamine D₂ receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .

HY-B1904A

Fluphenazine decanoate dihydrochloride	Dopamine Receptor	Neurological Disease
Fluphenazine decanoate dihydrochloride is a dopamine D₂ receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .

Cat. No.	Product Name	Type